Navigation Links
AFFiRiS AG Invests Into Human Capital - Chief Business Officer Recruited
Date:12/5/2011

VIENNA, December 5, 2011 /PRNewswire/ --

AFFiRiS AG announced today that Ali Alloueche is taking senior responsibility for their expanding business development activities. This new management position has been established as a result of the growing development pipeline of the Viennese biopharmaceutical company. As a member of the management team, Ali Alloueche will strategically and operationally support the development of AFFiRiS AG. Before joining AFFiRiS, Ali Alloueche was Head of External R&D at the leading vaccine manufacturer GlaxoSmithKline Biologicals, Belgium.

AFFiRiS AG has appointed Ali Alloueche as Chief Business Officer. In this position he will oversee business activities, strategic alliances and partnerships arising from the continuously growing pipeline of the Viennese biopharmaceutical company. Based on strong IP-positions and its AFFITOME©-technology, AFFiRiS has a diversified pipeline with four vaccine candidates currently in clinical phases and other attractive candidates in pre-clinical stage. Target indications include Alzheimer's, Parkinson's, Atherosclerosis and Hypertension - all diseases with unmet medical needs and attractive market potential.

Prior to joining AFFiRiS Ali Alloueche was Head External R&D at GlaxoSmithKline Biologicals in Belgium. In this position he expanded the company's R&D pipeline and extended its network of collaborators and business partners. In this role, he identified AFFiRiS's Alzheimer's vaccine candidates for GlaxoSmithKline - an activity in 2007 that culminated in a up to EUR 430 million-deal between both companies in October 2008. Prior to GlaxoSmithKline, Ali Alloueche was Research Director at Novartis Vaccines and Diagnostics in Italy and Head Translational Medicine and Scientific Affairs. Commenting on his new position, Ali Alloueche says: "AFFiRiS is one of the most dynamic biopharmaceutical companies in Europe. The company's focus on clinical programs and its robust financial position offer great business opportunities. I am excited about the opportunity to contribute to the further success of AFFiRiS at this particular stage of the company's development."

"Our growing development-pipeline creates more and more business opportunities," comments Walter Schmidt, co-founder and CEO of AFFiRiS, "Together with Ali we will exploit these opportunities further and add to our successful track record of business alliances. The experience he has gained in senior positions at two top ten pharmaceutical companies is a valuable addition to AFFiRiS's in-house expertise."

About AFFiRiS AG (date December 2011):

On the basis of the company's own patent positions AFFiRiS develops tailor-made peptide vaccines for Alzheimer's disease, Atherosclerosis, Parkinson's disease, Hypertension and several other conditions with unmet medical need and attractive market sizes. Alzheimer's is the current lead indication. For the Alzheimer's vaccine program, a license and option agreement with GlaxoSmithKline was closed in October 2008, triggering an upfront payment of EUR 22.5 million. The contract envisages (milestone-dependent) payments of up to EUR 430 million. A first milestone payment of EUR 10 million was made in October 2009 followed by EUR 3.5 million as announced recently. AFFiRiS currently employs 82 highly qualified staff at the Campus Vienna Biocenter in Vienna, Austria (http://www.affiris.com).

Contact AFFiRiS AG:
Julia Bock
Karl-Farkas-Gasse 22
1030 Vienna, Austria
T +43/(0)1/798-15-75-303
E  julia.bock@affiris.com  
W http://www.affiris.com


Editing & Distribution:
PR&D - Public Relations for Research & Education
Mariannengasse 8
1090 Vienna, Austria
T +43/(0)1/505-70-44
E contact@prd.at  
W http://www.prd.at



'/>"/>
SOURCE AFFiRiS AG
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
2. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
3. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
4. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
5. AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimers Vaccine Candidate AD02 into Clinical Phase II Testing
6. AFFiRiS AG: Vaccination Against Hypertension is Development Project No. 4 and has Already Been Awarded an FFG Grant of up to EUR 1.2 Million
7. AFFiRiS AG: Capital Increase: AFFiRiS Brings Santo VC and MIG 11 on Board
8. Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care: Carilion Clinic Teams Up with Retasure
9. Lockheed Martin Invests in Smart Grid Research and Development at Penn State University
10. Burrill & Company Invests in Taiwan Liposome Company
11. University of Lodz Invests in the Unique Cellaxess(R)HT System for Research on Multidrug Resistance Genes in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):